News

March 12, 2020March 12, 2020

CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial

News

Cellectar Biosciences has announced positive trial results demonstrating that its investigational therapy CLR 131 significantly reduced tumor activity, with tolerable safety, in B-cell lymphoma patients who received prior treatments. A ... Read more

March 10, 2020March 10, 2020

Tafasitamab Plus Revlimid Granted FDA Priority Review for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration (FDA) has granted priority review to MorphoSys’ application seeking approval of its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat people with ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the ... Read more

March 5, 2020March 5, 2020

Tipifarnib Granted FDA Fast Track Designation for T-cell Lymphomas

News

Kura Oncology‘s investigational lead therapy candidate tipifarnib was given fast track status by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with different subtypes ... Read more

March 3, 2020March 3, 2020

Tessa’s CD30 CAR T-cell Therapy for Lymphoma Granted RMAT Status by FDA

News

The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Tessa Therapeutics’ investigational CD30-targeted CAR T-cell therapy for treating relapsed or refractory classical Hodgkin’s lymphoma. ... Read more

February 27, 2020February 27, 2020

Corvus’ CPI-818 Shows Promising Early Results in T-cell Lymphomas, Data Finds

News

Twice-daily treatment with Corvus Pharmaceuticals‘ potential therapy for T-cell lymphomas, CPI-818, is showing promising safety and tolerability, and preliminary signs of efficacy, according to Phase 1/1b results. The early ... Read more

February 25, 2020February 26, 2020

CAR NK Cells Demonstrate High Response Rate and Safety in Lymphoma and Leukemia, Early Trial Shows

News

Natural killer (NK) cells — a type of immune system cell — engineered with a chimeric antigen receptor against CD19 completely eliminated tumors in 64% of people with non-Hodgkin’s ... Read more

February 20, 2020February 20, 2020

DPX-Survivac Triple Combo Holds Promise in Treating Advanced DLBCL, Phase 2 Trial Shows

News

IMV’s DPX-Survivac promotes anti-cancer responses and boosts the sensitivity of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to Keytruda (pembrolizumab) combined with chemotherapy, interim data from a Phase 2 study show. In the ... Read more

February 18, 2020February 18, 2020

CAR T-cell Therapy Liso-cel Under FDA Priority Review for Relapsed or Refractory Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has agreed to review Bristol-Myers Squibb’s request to approve the investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for treating adults with relapsed ... Read more

February 11, 2020February 11, 2020

FDA Grants Priority Review to Kite’s CAR T-cell Therapy KTE-X19 for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review Kite Pharma’s application requesting the approval of its investigational CAR T-cell therapy KTE-X19 for treating adult patients with relapsed ... Read more